Warm antibody autoimmune hemolytic anemia

Warm antibody autoimmune hemolytic anemia (WAIHA) is the most common form of autoimmune haemolytic anemia.[1] About half of the cases are of unknown cause, with the other half attributable to a predisposing condition or medications being taken. Contrary to cold autoimmune hemolytic anemia (e.g., cold agglutinin disease and paroxysmal cold hemoglobinuria) which happens in cold temperature (28–31 °C), WAIHA happens at body temperature.

Warm antibody autoimmune hemolytic anemia
Other namesWAIHA
SpecialtyHematology 

Causes

AIHA may be:

Medications

Pathophysiology

The most common antibody isotype involved in warm antibody AIHA is IgG, though sometimes IgA is found. The IgG antibodies attach to a red blood cell, leaving their FC portion exposed with maximal reactivity at 37 °C (versus cold antibody induced hemolytic anemia whose antibodies only bind red blood cells at low body temperatures, typically 28-31 °C). The FC region is recognized and grabbed onto by FC receptors found on monocytes and macrophages in the spleen. These cells will pick off portions of the red cell membrane, almost as if they are taking a bite. The loss of membrane causes the red blood cells to become spherocytes. Spherocytes are not as flexible as normal RBCs and will be singled-out for destruction in the red pulp of the spleen as well as other portions of the reticuloendothelial system. The red blood cells trapped in the spleen cause the spleen to enlarge, leading to the splenomegaly often seen in these patients.

There are two models for this: the hapten model and the autoantibody model. The hapten model proposes that certain drugs, especially penicillin and cephalosporins, will bind to certain proteins on the red cell membrane and act as haptens (small molecules that can elicit an immune response only when attached to a large carrier such as a protein; the carrier may be one that also does not elicit an immune response by itself). Antibodies are created against the protein-drug complex, leading to the destructive sequence described above. The autoantibody model proposes that, through a mechanism not yet understood, certain drugs will cause antibodies to be made against red blood cells which again leads to the same destructive sequence. It is possible for it to occur in an immunocompromised patient.[3]

Diagnosis

Diagnosis is made by a positive direct Coombs test, other lab tests, and clinical examination and history. The direct Coombs test looks for antibodies attached to the surface of red blood cells.

Clinical findings

Laboratory findings include severe anemia, normal MCV (means corpuscular value) , and hyperbilirubinemia (from increased red cell destruction) that can be of the conjugated or unconjugated type.

Treatment

Corticosteroids and immunoglobulins are two commonly used treatments for warm antibody AIHA. Initial medical treatment consists of prednisone. If ineffective, splenectomy should be considered.

If refractory to both these therapies, other options include rituximab,[4][5] danazol, cyclosphosphamide, azathioprine, or ciclosporin.High-dose intravenous immune globulin may be effective in controlling hemolysis, but the benefit is short lived (1–4 weeks), and the therapy is very expensive.

See also

References
  1. Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 637. ISBN 0-7216-0187-1.
  2. AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA) Archived 2009-10-07 at the Wayback Machine By J.L. Jenkins. The Regional Cancer Center. 2001
  3. Nowak-Wegrzyn A, King KE, Shirey RS, Chen AR, McDonough C, Lederman HM (May 2001). "Fatal warm autoimmune hemolytic anemia resulting from IgM autoagglutinins in an infant with severe combined immunodeficiency". J. Pediatr. Hematol. Oncol. 23 (4): 250–2. doi:10.1097/00043426-200105000-00015. PMID 11846306.
  4. Morselli M, Luppi M, Potenza L, et al. (May 2002). "Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment". Blood. 99 (9): 3478–9. doi:10.1182/blood-2002-01-0018. PMID 12001903.
  5. Bussone G, Ribeiro E, Dechartres A, et al. (December 2008). "Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: Retrospective analysis of 27 cases". Am. J. Hematol. 84 (3): 153–7. doi:10.1002/ajh.21341. PMID 19123460. S2CID 205292170.
Classification
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.